Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Oragenics Inc

OGEN ✓ COMPLIANTFree checks used up today ☆ Track — members

NYSE MKT · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: N/A

Last Close

$0.49

▼ -0.23%

Market Cap $2.19M · Vol 737

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$2.19M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

46.73

Momentum

Beta

1.26

vs Market

52W High

$1.45

66.55% below

52W Low

$0.47

3.46% above

Volume

737

Avg 3.02K

P/B

0.40

Price-to-book

ROE

N/A

Return on equity

Free Float

98.07%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Oragenics Inc (OGEN) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does OGEN pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+1.04%

-4.90%

-16.38%

-17.05%

YTD

-38.07%

-62.69%

-99.53%

-99.95%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-9,842,490.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-172.95% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	0.40
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	4.51M

Technical Indicators

50-Day SMA	$0.51
200-Day SMA	$0.64
RSI (14)	46.73
Beta	1.26
52-Week High	$1.45
52-Week Low	$0.47

Volume Today	737
Avg Daily Volume (30D)	3.02K
Relative Volume	0.24x
Volatility (10D)	47.70
Volatility (30D)	54.02
Free Float	98.07%

Analyst Consensus

N/A

Current Price $0.49

Mean Target N/A

52W Low$0.47 52W High$1.45

Current

Target

$0.47 $1.45

Current Analyst target

· 0 analysts

Identifiers

ExchangeNYSE MKT

FIGIBBG001SL28N5

ISINUS6840236094

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. +2.92% ARGX.BR argenx SE +2.76% ARGX argenx SE +1.93% 2269.HK WuXi Biologics (Cayman) Inc. +4.51% GMAB Genmab A/S -1.77%

Company Profile

Oragenics, Inc. is a development-stage company. It is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. It focuses on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI or Concussion), and for treating Niemann Pick Disease Type C (NPC), and proprietary powder formulation and an intranasal delivery device. Its lead product, ONP-002, is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. It is also focused on developing medical products that treat brain related illnesses and diseases (the Neurology Assets). Its other product candidate, ONP-001, is in its early stage and clinical trials.